Literature DB >> 1988080

Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells.

M Watanabe1, N Komeshima, M Naito, T Isoe, N Otake, T Tsuruo.   

Abstract

We previously reported that MX2, a new morpholino anthracycline, showed marked effects on pleiotropic drug-resistant sublines of murine P388 leukemia in vivo as well as in vitro. In this study we examine the in vitro cytotoxicity against pleiotropic drug-resistant sublines of human tumor cell lines. MX2 was effective against multidrug-resistant sublines of four human tumor cell lines; these cells, having a 4.8- to 200-fold cross-resistance to Adriamycin (ADM) showed only a 0.7- to 2.3-fold resistance to MX2 compared with the sensitive cells. To elucidate the mechanism by which MX2 overcomes multidrug resistance, the intracellular pharmacology of MX2 in human myelogenous leukemia K562 and its ADM-resistant subline (K562/ADM) was examined. Both K562 and K562/ADM cells accumulated MX2 more easily than ADM, and the intracellular accumulation of MX2 attained a steady state in both cell lines within 30 min of incubation at 37 degrees C. The amount of MX2 that accumulated in K562/ADM at a steady state was only 1.3 times lower than that in K562. However, ADM was accumulated slowly in both cell lines compared with MX2, and the intercellular concentration reached a steady state in K562/ADM after 90 min of incubation and in K562 after more than 120 min. K562/ADM cells accumulated a 3.3-fold lower concentration of ADM than K562 after 120 min of exposure. The steady-state concentration of ADM in K562/ADM was 8.3 times lower than that of MX2. In addition, greater than 70% of MX2 was retained in both cell lines after 150 min of incubation in the absence of this drug. Verapamil, a calcium antagonist, hardly augmented the cytotoxicity of MX2 against K562/ADM, and no distinct effect of this drug on both the time course and the maximal level of accumulation of MX2 was observed. Interestingly, MX2 effectively inhibited ATP/Mg2(+)-dependent [3H]vincristine binding to K562/ADM membrane preparations, indicating that MX2 could be transported outside the cell by an active efflux pump. The high intracellular accumulation and retention of MX2 in K562/ADM through the rapid influx of the drug into the cells may be one of the reasons why MX2 circumvents pleiotropic drug resistance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.

Authors:  J Kuratsu; N Arita; K Kurisu; T Uozumi; T Hayakawa; Y Ushio
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

2.  Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.

Authors:  S Mizumatsu; K Matsumoto; Y Ono; T Tamiya; T Furuta; T Ohmoto
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

3.  Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.

Authors:  M Ripamonti; L Capolongo; G Melegaro; C Gornati; A Bargiotti; M Caruso; M Grandi; A Suarato
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Isolation and characterization of a mitomycin C-resistant variant of human colon carcinoma HT-29 cells.

Authors:  J H Lee; M Naito; M Nakajima; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells.

Authors:  A Schaefer; J Westendorf; K Lingelbach; C A Schmidt; D L Mihalache; A Reymann; H Marquardt
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.

Authors:  A A Ebrahim el-Zayat; M A Izquierdo; G M Clark; D D Von Hoff
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

7.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.

Authors:  X F Hu; A Slater; D Rischin; P Kantharidis; J D Parkin; J Zalcberg
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

8.  Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.

Authors:  T Asano; K Nakamura; H Fujii; N Horichi; T Ohmori; K Hasegawa; T Isoe; M Adachi; N Otake; Y Fukunaga
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

9.  Genome-wide DNA methylation profiling of CpG islands in a morpholino anthracycline derivative-resistant leukemia cell line: p38α as a novel candidate for resistance.

Authors:  Takeshi Asano; Hidehiko Narazaki; Atsushi Fujita
Journal:  Pharmacol Res Perspect       Date:  2016-12-29

10.  Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase.

Authors:  K Mikami; M Naito; T Ishiguro; H Yano; A Tomida; T Yamada; N Tanaka; T Shirakusa; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1998-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.